Olena Tsyryuk

Olena Tsyryuk

Auto-generated profile, based on publicly available information

Olena Tsyryuk

School of Medicine, Taras Shevchenko National University of Kyiv, Volodymyrska Street 64/13, 01601 Kiev, Ukraine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ludovico AbenavoliLudovico Abenavoli
Ludovico Abenavoli
TFTetyana Falalyeyeva
Tetyana Falalyeyeva
Luigi BoccutoLuigi Boccuto
Luigi Boccuto
OTOlena Tsyryuk
Olena Tsyryuk
NKNazarii Kobyliak
Nazarii Kobyliak
The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.